DA-EPOCH-R improves the outcome over that of R-CHOP regimen for DLBCL patients below 60 years, GCB phenotype, and those with high-risk IPI, but not for double expressor lymphoma.
Xin-Yu ZhangJin-Hua LiangLi WangHua-Yuan ZhuWei WuLei CaoLei FanJian-Yong LiWei XuPublished in: Journal of cancer research and clinical oncology (2018)
GCB DLBCL, younger patients, and high-risk patients, but not DEL patients, may benefit from continuous-infusion DA-EPOCH-R regimen.